Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RGO.F | 9995.HK | ROIV | 4593.T | RPRX | 214450.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 85.11B | 40.23B | 27.61B | 33.08B | 39.04B | 2.34T |
| P/E (TTM) | 21.1 | 6.1 | — | 235.6 | 44.2 | — |
| Forward P/E | 18.6 | 46.7 | -27.5 | -8.6 | 11.6 | — |
| Price/book | 2.8 | 3.8 | 6.5 | 3.8 | 4.5 | — |
| Dividend yield | 0.39% | — | — | — | 1.39% | 1.66% |
| 1-year change | +50.09% | −19.94% | +85.85% | −47.95% | +64.28% | −56.00% |
| Today | −2.29% | +1.49% | +6.08% | −3.54% | +1.75% | +0.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All RGO.F news ›Regeneron Pharmaceuticals (REGN) share price
Regeneron Pharmaceuticals Inc Stock Price Live, Charts & News The Economic Times
Regeneron Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
(NASDAQ:REGN) 2026-11-03 Seeking Alpha The following slide deck was published by Regeneron Pharmaceuticals, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-10-30 Earnings Summary
More from 1 other outlet
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Truist Financial
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Truist Financial - Truist Financial raised Regeneron’s price target from $780 to $982 and maintained a “buy” rating. Othe
Bernstein maintains Regeneron Pharmaceuticals at Market Perform, raises price target to $812 from $756
TradingView Bernstein maintained Regeneron Pharmaceuticals at Market Perform and raised its price target to $812 from $756, a 7.4% increase. The price target implies a downside of 12.5% from the Oc
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $997.00 Price Target at Leerink Partners
MarketBeat Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $997.00 Price Target at Leerink Partners - Leerink Partners raised Regeneron’s price target from $835 to $997 while maintaining a “market perform”
More from 1 other outlet
Truist Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $982 from $780
TradingView Truist Securities maintained Regeneron Pharmaceuticals at Buy and raised its price target to $982 from $780, a 25.9% increase. The price target implies an upside of 5.8% from the Oct 30 cl
Wells Fargo maintains Regeneron Pharmaceuticals at Equal-Weight, raises price target to $925 from $750
TradingView Wells Fargo maintained Regeneron Pharmaceuticals at Equal-Weight and raised its price target to $925 from $750, a 23.3% increase. The price target is roughly in line with the Oct 30 clo
[Regeneron Pharmaceuticals Q3 2026 Earnings Call] Regeneron Q3 revenue jumps 36% to $5.1B, EPS surges 70% as Dupixent, EYLEA HD, Libtayo hit records
Regeneron Pharmaceuticals delivered another standout quarter, with total revenue climbing 36% year-over-year to $5.1 billion and non-GAAP diluted EPS surging 70% to $20.07, driven by record sales of its key growth drivers—Dupixent, EYLEA…
REGENERON PHARMACEUTICALS ($REGN) Releases Q3 2026 Earnings
REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results for Q3 2026 on Friday, October 30th. The company reported earnings of $20.07 per share, beating estimates of $16.48 by $3.59. The company also reported revenue of…
More from 1 other outlet
Analyst recommendations: Adobe, Caterpillar, Fair Isaac, Regeneron Pharmaceuticals…
Every morning, find a selection of analysts' recommendations covering North America. The list only includes companies that have received a rating or price target change, or new analyst coverage. It... -November 02, 2026 at 05:49 am EST -…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com22
- marketbeat.com20
- themarketsdaily.com11
- tradingview.com10
- defenseworld.net6
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 82 articles, not a forecast.